Search results
Bryhali dosage: Form, strength, how to use, and more
Medical News Today· 4 days agoBryhali (halobetasol) is a brand-name drug prescribed to treat plaque psoriasis in adults. Bryhali belongs to a drug
IPC Develops Consensus on Generalized Pustular Psoriasis
Medscape· 6 days agoThe IPC's definition and diagnostic criteria for GPP minimized the complexity of clinical...
Stelara interactions: Other medications, alcohol, and more
Medical News Today· 4 days agoStelara (ustekinumab) is a brand-name injectable drug prescribed for certain autoimmune conditions....
VYNE Therapeutics receives FDA approval for trial of VYN202
Clinical Trials Arena via Yahoo Finance· 7 days agoAround 64 healthy adult participants will be enrolled across five SAD and three MAD cohorts in the...
Merck and other pharma giants are bracing for competition to their blockbuster drugs. Here's how.
Quartz· 6 days agoEvery pharmaceutical company is constantly searching for its next blockbuster — the billion-dollar ...
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
InvestorPlace via Yahoo Finance· 7 days agoAmid a challenging market environment, one of your best bets could be to target biotech stocks to...
Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update
Morningstar· 6 days agoEntered into a worldwide license and collaboration agreement for rusfertide with Takeda; Cash runway extended through Q4 2027[1]Enrollment in both Phase 3 ICONIC LEAD and ICONIC TOTAL trials ...
3 Tried and True Dividend Stocks to Buy for Your Portfolio
InvestorPlace via Yahoo Finance· 7 days agoPicking income stocks can be challenging. Some companies pay dividends only to cut them in the...
5 Best Undervalued Stocks To Buy In May 2024
Forbes· 5 days agoResearching undervalued stocks? We examined stocks to identify the top undervalued stocks in May 2024. Dive into the results here.
Celltrion USA's adalimumab-aaty biosimilar to HUMIRA® now available at low wholesale acquisition...
Rome Sentinel· 4 days agoAdalimumab-aaty is also available from Celltrion USA under the brand name YUFLYMA®, which launched in July 2023 and is available at a 5% discount to the current WAC list price of HUMIRA. Adalimumab-aaty ...